Rhythm Pharmaceuticals Reports Third-Quarter 2026 Results and Business Update
Rhythm Pharmaceuticals reported strong U.S. launch momentum for IMCIVREE for acquired hypothalamic obesity.
Story updates
12:07:09 PM UTC
SquawkNews
Rhythm Pharmaceuticals 3Q Loss/Shr 61c >RYTM
12:07:17 PM UTC
SquawkNews
Rhythm Pharmaceuticals 3Q Loss $42.4M >RYTM
12:12:35 PM UTC
SquawkNews
Rhythm Pharmaceuticals 3Q Rev $92.1M >RYTM